How is the Somatic Cell Genome Editing Program Health Relevant?
Many diseases are caused by harmful changes, or mutations, in a person’s DNA. These genetic diseases include common diseases such as cancer and diabetes. Most rare diseases are also caused by DNA mutations such as, Duchenne Muscular Dystrophy, Huntington’s Disease, and Cystic Fibrosis. While each of the many thousands of rare diseases affects a small number of individuals, millions of Americans live with rare diseases, many of which have no current treatment options available.
Recent scientific advances in correcting these DNA mutations have made the possibility of treating, and even curing, genetic diseases much closer to reality. Research in this technology, referred to as genome editing, has increased at a tremendous pace, and the first clinical trials to use genome editing in humans are already underway. However, to fully realize the vision of treating many genetic diseases, several obstacles need to be overcome. One significant challenge to treating specific diseases is that it will often require making changes to the DNA in the cells affected by the mutation. And there are a wide variety of cells - in different parts of the body - that can be compromised in different genetic diseases. Getting genome editing tools into the various cells of the body will require the development of delivery methods specialized to the target cell type and location within the body.
Because of this challenge, the SCGE program is funding multiple projects that focus on a variety of strategies for delivering genome editing tools to different cells within the body that can be affected by genetic diseases. The image below describes how these projects are working together to help reduce the burden of disease caused by genetic changes.
Learn More About SCGE
An audio described version of this video is also available.